AbbVie concludes training for KSU pharmacy students

AbbVie concludes training for KSU pharmacy students

349
0
SHARE
KSU graduating pharmacy college student gets certificate of recognition
KSU graduating pharmacy college student gets certificate of recognition

ABBVIE, the global research-based biopharmaceutical company, has successfully concluded its most recent five-week training program for soon-to-graduate students from the College of Pharmacy of King Saud University (KSU).

In line with the Saudi Vision 2030, industries are to achieve self-reliance while maintaining global standards. The AbbVie training program was designed to provide participants with the practical knowledge and personal skills to be successful contributors in the biopharmaceutical workplace. The most recent program follows a series of training programs that AbbVie has developed for the Saudi youth.

“The AbbVie training program is a real asset for the local pharmaceuticals industry in Saudi Arabia,” commented Rami Fayed, General Manager, AbbVie, Saudi Arabia. “It helps the young Saudi Pharmacy students to start out on their careers with a firm grasp of what to expect once they enter the pharmaceuticals workplace.”

“This training program adds an extra layer to our students’ education that could only be learnt with global biopharmaceutical companies such as AbbVie,” said Dr. Haitham Al Rabiah, Interim Dean of the College of Pharmacy at King Saud University. “It provides an invaluable introduction to what to expect once they leave academia and enter the pharmaceutical profession.”

The training program covered workaday topics as Supply Chain Management, Governmental Affairs, Regulatory Affairs, Pharmacovigilance, Compliance and Public Affairs. Other sessions focused on self-improvement and assessment processes including “How to Improve Your Memory”, Communications, Active Listening, Innovation and Emotional Intelligence, all part of the worldwide standard of instruction for those entering the medical professions. — SG

NO COMMENTS

LEAVE A REPLY